# NCT05468489 (NCT05468489)

> To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05468489
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Shanghai Henlius Biotech
- Conditions: Extensive Stage Small Cell Lung Cancer
- Interventions: Serplulimab + chemotherapy (carboplatin-etoposide); Atezolizumab + chemotherapy (carboplatin-etoposide)
- Enrollment: 200
- Primary outcome: OS

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05468489